15 results about "Cetuximab" patented technology

The invention relates to a preparation of an antibody drug, which belongs to the field of biological medicines, is used for a preparation of a high-concentration antibody drug with an anti-oxidation requirement, and also has an anti-degradation capability. The preparation contains 20 mmol / L to 30 mmol / L of L-methionine and 200 mmol / L of trehalose, and is particularly suitable for being used for preparing Jukoulikumab, omaszumab and cetuximab. The preparation not only has a better anti-oxidation effect, but also can realize a synergistic stabilization effect by combining high-concentration L-Met with 200 mM trehalose, has anti-degradation ability, is widely applicable to various therapeutic antibodies, and provides an extensible solution for improving the stability and shelf life of a high-concentration biological preparation.

The application belongs to the field of tumor molecular diagnosis and targeted therapy, and specifically finds lncRNA RP11-499F3.2 which is significantly highly expressed in head and neck cancer through bioinformatics analysis of TCGA data; it is verified through clinical samples that the expression level of RP11-499F3.2 in head and neck squamous cell carcinoma is significantly higher than that in paracancerous tissues, and is closely related to the clinical prognosis of patients with head and neck squamous cell carcinoma; it is found through functional experiments that high expression of RP11-499F3.2 can promote the in-vitro proliferation, migration and invasion of head and neck squamous cell carcinoma cells; meanwhile, it is also found that RP11-499F3.2 can promote the drug resistance of head and neck squamous cell carcinoma cells to cetuximab; the disclosed lncRNA RP11-499F3.2 helps to reveal the new pathogenesis of head and neck cancer, provides a new tumor marker for the prognosis monitoring of head and neck cancer, and provides a new idea for the clinical treatment of head and neck cancer.

Provided herein are combination therapies comprising a SHP2 inhibitor (e.g., Compound 1) and an EGFR inhibitor (e.g., osimertinib or cetuximab) and methods of using such combination therapies.

The efficacy and indication of cetuximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

To provide effective cancer treatments. [Solution] The present invention provides a cancer treatment method that combines a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), and standard therapy (e.g., combination therapy of FOLFOX therapy with bevacizumab or cetuximab for unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a reduced-dose regimen for pancreatic cancer with distant metastases).

Provided include methods, compositions and kits for treating cancer (e.g., RASWT colorectal cancer) in a subject. The method can comprise administrating an a PLK1 inhibitor (for example, onvansertib) or a combination of a PLK1 inhibitor and an EGFR inhibitor to the subject in a manner sufficient to inhibit progression of the cancer.

The present invention relates to: an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 or an antigen-binding fragment thereof; and a pharmaceutical composition for treating cancer, comprising same as an active ingredient. The antibody-drug conjugate of the present invention comprises an antibody specifically targeting GRP94 and having strong internalization activity, and, as a result of conjugation with a cytotoxic agent, effectively inhibits the growth of cetuximab-resistant CRC cell lines including HT29, HCT116, HCT8 and LoVo cells, and thus can be effectively used as a therapeutic agent for various carcinomas in which GRP94 is overexpressed.

The invention described in the disclosure relates to a panel of biomarkers for determining the responsiveness of a cancer patient treated or to be treated by cetuximab. The disclosure provides methods and compositions, e.g., kits, for evaluating the biomarkers and methods of using such biomarkers to predict a cancer patient's response to cetuximab. Such information can be used in determining prognosis and treatment options for gastric cancer patients.

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

The application discloses a Fab-BH3 fusion protein and a preparation method and application thereof, belongs to the technical field of biological medicines, and particularly relates to a Fab-BH3 fusion protein, wherein the amino acid sequence of the Fab-BH3 fusion protein is shown as SEQ ID NO. 2. The application also discloses an application of the Fab-BH3 fusion protein in preparation of a drug for treating non-small cell lung cancer. The Fab-BH3 fusion protein is formed by coupling a cetuximab Fab fragment and a BH3 polypeptide, does not affect the activity of the cetuximab, inhibits the growth of non-small cell lung cancer cells with overexpressed EGFR, and improves the treatment effect on non-small cell lung cancer.

The present invention relates to a benzamide derivative, a preparation method therefor, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of cancer. The benzamide derivative provided in an aspect of the present invention can be used for preventing or treating cancer by suppressing EGFR mutation, and exhibits a remarkable synergy effect on anticancer activity when administered in combination with an EGFR antagonist such as Cetuximab, thus finding advantageous uses as an anticancer agent.

The invention relates to a cetuximab modified nanostructure lipid carrier loaded with p-QM-1h as well as preparation and application of the cetuximab modified nanostructure lipid carrier. A nanoliposome loaded with a therapeutic active drug p-QM-1h is covalently coupled with cetuximab CTX of a high-expression EGFR (epidermal growth factor receptor) in a targeted tumor; the economic cost is low, the encapsulation efficiency is relatively high, and the solubility of p-QM-1h is effectively improved; the nano-particles are uniform, good in dispersion and stability and good in anti-tumor activity.

The invention discloses an antibody coupling medicine for targeting colorectal cancer cells and a preparation method of the antibody coupling medicine, and belongs to the technical field of biological medicine. The antibody coupling drug is formed by connecting cetuximab, atorvastatin or a derivative thereof and a specific connexon through covalent bonds and is constructed by adopting a site specific coupling technology, the average drug-antibody ratio is 3.13, and the monomer purity is greater than or equal to 97%. The connexon can be broken in response to acidity, high reducibility or high cathepsin expression conditions of a tumor microenvironment, so that accurate release of the effective load is realized. The invention also discloses a preparation method of the antibody coupling drug, which comprises the steps of antibody reduction, active intermediate preparation, coupling, quenching and purification, and the yield is greater than or equal to 85%. The antibody coupling drug can specifically target EGFR high-expression KRAS mutant colorectal cancer cells, reverses the drug resistance of tumors to an EGFR inhibitor by inhibiting a mevalonic acid pathway, remarkably reduces the systemic toxicity of atorvastatin, and has excellent curative effect and safety.

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.